var data={"title":"Cefprozil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefprozil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5844?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefprozil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefprozil: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cefprozil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefprozil: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147858\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cefprozil;</li>\n      <li>Auro-Cefprozil;</li>\n      <li>Ava-Cefprozil;</li>\n      <li>Cefzil;</li>\n      <li>RAN-Cefprozil;</li>\n      <li>Sandoz-Cefprozil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147883\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Second Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147861\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial exacerbation of chronic bronchitis:</b> Oral: 500 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis/tonsillitis:</b> Oral: 500 mg every 24 hours for 10 days (administer for &ge;10 days if due to <i>S. pyogenes</i>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin-structure infections, uncomplicated:</b> Oral: 250 to 500 mg every 12 hours, or 500 mg every 24 hours for 10 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147873\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cefprozil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefprozil: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial exacerbation of chronic bronchitis: </b>Children &gt;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media:</b> Oral: Infants &ge;6 months and Children: 15 mg/kg/dose every 12 hours for 10 days (maximum: 500 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis/tonsillitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 12 years: Oral: 7.5 mg/kg/dose every 12 hours for 10 days (administer for &ge;10 days if due to <i>S. pyogenes</i>) (maximum: 500 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin-structure infections, uncomplicated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 12 years: Oral: 20 mg/kg/day once every 24 hours for 10 days (maximum: 1,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection (off-label use):</b> Infants and Children 2 to 24 months: Oral: 15 mg/kg/dose twice daily for 7 to 14 days (AAP, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147862\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147863\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Manufacturer's labeling:</i> Infants, Children, Adolescents, and Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;30 mL/minute: Reduce dose by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">End-stage renal disease (ESRD) on hemodialysis: Give dose after dialysis on dialysis days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Alternative recommendations (Aronoff, 2007):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;50 mL/minute: Administer 50% of usual dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intermittent hemodialysis (IHD): Supplement with 250 mg after dialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peritoneal dialysis: Administer 50% of usual dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants, Children, and Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Recommendations based on 30 mg/kg/day divided every 12 hours in patients with normal renal function:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &lt;29 mL/minute/1.73 m<sup>2</sup>: 7.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">ESRD on hemodialysis: 7.5 mg/kg/dose every 12 hours; supplement with 5 mg/kg/dose after dialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Peritoneal dialysis: 7.5 mg/kg/dose every 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682547\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147835\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (50 mL, 75 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147820\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147839\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer without regard to meals. Administer around the clock to promote less variation in peak and trough serum levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147838\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial exacerbation of chronic bronchitis:</b> Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis caused by <i>S. pneumoniae</i>, <i>H. influenzae</i> (including beta-lactamase&ndash;producing strains), and <i>M. catarrhalis</i> (including beta-lactamase&ndash;producing strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media: </b>Treatment of mild to moderate otitis media caused by <i>S. pneumoniae</i>, <i>Haemophilus influenzae</i> (including beta-lactamase&ndash;producing strains), and <i>Moraxella (Branhamella) catarrhalis</i> (including beta-lactamase&ndash;producing strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis/tonsillitis:</b> Treatment of mild to moderate pharyngitis/tonsillitis caused by <i>Streptococcus pyogenes</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Cefprozil is generally effective in the eradication of <i>S. pyogenes</i> from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin-structure infections, uncomplicated:</b> Treatment of mild to moderate uncomplicated skin and skin-structure infections caused by <i>Staphylococcus aureus</i> (including penicillinase-producing strains) and <i>S. pyogenes</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28616442\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Community-acquired pneumonia treatment in children 3 months to younger than 12 years caused by S. pneumoniae; Urinary tract infections in children (empiric)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147890\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefprozil may be confused with ceFAZolin, cefuroxime </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefzil may be confused with Ceftin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147827\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaper rash (2%), genital pruritus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (4%), diarrhea (3%), abdominal pain (1%), vomiting (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum transaminases (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Superinfection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, arthralgia, cholestatic jaundice, confusion, drowsiness, eosinophilia, erythema multiforme, fever, headache, hyperactivity, increased blood urea nitrogen, increased serum creatinine, insomnia, leukopenia, pseudomembranous colitis, serum sickness, skin rash, Stevens-Johnson syndrome, thrombocytopenia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147842\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefprozil, any component of the formulation, or other cephalosporins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147824\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity:  If a serious hypersensitivity reaction occurs, discontinue and institute emergency supportive measures, including airway management and treatment (eg, epinephrine, antihistamines and/or corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease:  Use with caution in patients with a history of gastrointestinal disease, particularly colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982). Some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer's  labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298994\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147829\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9225&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147853\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food delays cefprozil absorption. Management: May administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147831\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5956626\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147845\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small amounts of cefprozil are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefprozil to nursing women. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147846\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Oral suspension may contain phenylalanine; consult product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147833\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal function at baseline and as clinically indicated. Monitor for signs of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147823\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147841\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed (95%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.23 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~36%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children (6 months to 12 years): 1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Normal hepatic and renal function: 1.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal impairment: 5.2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal failure: 5.9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hepatic impairment: 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Fasting: 1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~60% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323050\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cefprozil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (75 mL): $31.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (75 mL): $57.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cefprozil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $437.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $452.19</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147847\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aprozil (BD);</li>\n      <li>Aurozil (ET);</li>\n      <li>Cefproz (AE, LB, QA, SA);</li>\n      <li>Cefrozil (KR);</li>\n      <li>Cefzil (AE, BB, BD, BG, BH, BM, BS, BZ, CN, CZ, EE, EG, GB, GR, GY, HN, JM, JO, KR, KW, LB, LT, NL, PL, SA, SI, SK, SR, TT);</li>\n      <li>Cerofazil (KR);</li>\n      <li>Cesilpro (KR);</li>\n      <li>Cronocef (IT);</li>\n      <li>Lizor (ID);</li>\n      <li>Orprozil (IN);</li>\n      <li>Pathozil (BD);</li>\n      <li>Procef (AR, AT, CH, CO, EC, HK, MX, MY, PH, PT, SG, TH, TR, VE);</li>\n      <li>Prozef (ZA);</li>\n      <li>Quzil (JO);</li>\n      <li>Zilapro (BD);</li>\n      <li>Zilpro (PK);</li>\n      <li>Zilroz (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants 2 to 24 months. Pediatrics. 2011;128(3):595-610. http://pediatrics.aappublications.org/content/128/3/595.full.21873693</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arguedas AG, Zaleska M, Stutman HR, et al, &ldquo;Comparative Trial of Cefprozil vs Amoxicillin Clavulanate Potassium in the Treatment of Children With Acute Otitis Media With Effusion,&rdquo; <i>Pediatr Infect Dis J</i>, 1991, 10(5):375-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/1906160/pubmed\" target=\"_blank\" id=\"1906160\">1906160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barriere SL, &ldquo;Review of <i>In Vitro</i> Activity, Pharmacokinetic Characteristics, Safety, and Clinical Efficacy of Cefprozil, a New Oral Cephalosporin,&rdquo; <i>Ann Pharmacother</i>, 1993, 27(9):1082-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/8219444/pubmed\" target=\"_blank\" id=\"8219444\">8219444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefprozil [prescribing information]. Princeton, NJ: Sandoz Inc; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefzil (cefprozil) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gainer RB 2nd, &ldquo;Cefprozil: A New Cephalosporin; Its Use in Various Clinical Trials,&rdquo; <i>South Med J</i>, 1995, 88(3):338-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/7886533/pubmed\" target=\"_blank\" id=\"7886533\">7886533</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lowery N, Kearns GL, Young RA, et al, &ldquo;Serum Sickness-Like Reactions Associated With Cefprozil Therapy,&rdquo; <i>J Pediatr</i>, 1994, 125(2):325-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/8040786/pubmed\" target=\"_blank\" id=\"8040786\">8040786</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schatz BS, Karavokiros KT, Taeubel MA, et al, &ldquo;Comparison of Cefprozil, Cefpodoxime Proxetil, Loracarbef, Cefixime, and Ceftibuten,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(3):258-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/8833562/pubmed\" target=\"_blank\" id=\"8833562\">8833562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shukla UA, Pittman KA, and Barbhaiya RH, &ldquo;Pharmacokinetic Interactions of Cefprozil With Food, Propantheline, Metoclopramide, and Probenecid in Healthy Volunteers,&rdquo; <i>J Clin Pharmacol</i>, 1992, 32(8):725-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/1487562/pubmed\" target=\"_blank\" id=\"1487562\">1487562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shyu WC, Pittman KA, Wilber RB, et al, &ldquo;Pharmacokinetics of Cefprozil in Healthy Subjects and Patients With Hepatic Impairment,&rdquo; <i>J Clin Pharmacol</i>, 1991, 31(4):372-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefprozil-drug-information/abstract-text/2037711/pubmed\" target=\"_blank\" id=\"2037711\">2037711</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9225 Version 149.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147858\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F147883\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F147861\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F147873\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F147862\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F147863\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682547\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147835\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F147820\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F147839\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F147838\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28616442\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147890\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147827\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147842\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147824\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298994\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147829\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F147853\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147831\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5956626\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F147845\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F147846\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F147833\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147823\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F147841\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323050\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147847\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9225|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefprozil-patient-drug-information\" class=\"drug drug_patient\">Cefprozil: Patient drug information</a></li><li><a href=\"topic.htm?path=cefprozil-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefprozil: Pediatric drug information</a></li></ul></div></div>","javascript":null}